Nls Pharmaceutics LTD. (NCEL) SEC Filings — 2024
50 SEC filings for Nls Pharmaceutics LTD. (NCEL) in 2024.
Filings
- NLS Pharma & Kadimastem File F-4 for Merger — 6-K · Dec 30, 2024
- NLS Pharmaceutics Schedules Shareholder Meeting for Jan 14 — 6-K · Dec 23, 2024
- NLS Pharma & Kadimastem Seek FDA Meeting for Diabetes Treatment — 6-K · Dec 19, 2024
- NLS Pharmaceutics Schedules Shareholder Meeting for Jan 7 — 6-K · Dec 17, 2024
- NLS Pharmaceutics CEO Letter to Shareholders Filed — 6-K · Dec 11, 2024
- NLS Pharmaceutics Ltd. Announces Private Placement — 6-K · Dec 4, 2024
- NLS Pharmaceutics Announces Promising Preclinical Data — 6-K · Dec 3, 2024
- Nls Pharmaceutics LTD. SC 13G/A Filing — SC 13G/A · Nov 21, 2024
- NLS Pharma Advances Novel Narcolepsy Drug Candidates — 6-K · Nov 18, 2024
- NLS Pharmaceutics Director Resigns — 6-K · Nov 15, 2024
- Nls Pharmaceutics LTD. SC 13G Filing — SC 13G · Nov 14, 2024
- Nls Pharmaceutics LTD. SC 13G/A Filing — SC 13G/A · Nov 14, 2024
- NLS Pharmaceutics to Merge with Kadimastem Ltd. — 6-K · Nov 12, 2024
- NLS Pharmaceutics Shareholders Approve All Agenda Items — 6-K · Nov 8, 2024
- NLS Pharmaceutics Schedules Shareholder Meeting for Nov 8 — 6-K · Nov 6, 2024
- NLS Pharmaceutics to Merge with Kadimastem Ltd. — 6-K · Nov 5, 2024
- NLS Pharmaceutics to Merge with Kadimastem — 6-K · Nov 4, 2024
- Nls Pharmaceutics LTD. SC 13G/A Filing — SC 13G/A · Nov 4, 2024
- NLS Pharmaceutics Regains Nasdaq Compliance — 6-K · Oct 28, 2024
- NLS Pharma Converts Debt to Equity, Issues Shares — 6-K · Oct 22, 2024
- NLS Pharmaceutics Ltd. Files Interim Financials — 6-K · Oct 18, 2024
- NLS Pharmaceutics Closes Private Placement, Eyes Nasdaq Compliance — 6-K · Oct 15, 2024
- NLS Pharmaceutics Closes Private Placement — 6-K · Oct 11, 2024
- NLS Pharmaceutics Regains Nasdaq Bid Price Compliance — 6-K · Oct 10, 2024
- NLS Pharmaceutics Shareholders Approve All Agenda Items — 6-K · Oct 8, 2024
- NLS Pharmaceutics Changes EGM Record Date — 6-K · Oct 1, 2024
- NLS Pharmaceutics Increases Share Capital — 6-K · Sep 25, 2024
- NLS Pharmaceutics Shareholders Approve All Agenda Items — 6-K · Sep 19, 2024
- NLS Pharmaceutics Amends Warrant Agreement — 6-K · Sep 17, 2024
- NLS Pharmaceutics Terminates Nolazol License with Eurofarma — 6-K · Sep 13, 2024
- NLS Pharmaceutics Schedules Shareholder Meetings for September 18 — 6-K · Aug 26, 2024
- NLS Pharmaceutics Ltd. Shareholders Approve Agenda Items, Elect New Auditor — 6-K · Aug 15, 2024
- NLS Pharmaceutics CFO Elena Thyen Terminated — 6-K · Aug 14, 2024
- NLS Pharmaceutics and Kadimastem Announce Merger Term Sheet — 6-K · Jul 30, 2024
- NLS Pharmaceutics prices $0.79M direct offering — 6-K · Jul 1, 2024
- NLS Pharmaceutics Announces Parkinson's Preclinical Results — 6-K · Jun 27, 2024
- NLS Pharmaceutics Gets Nasdaq Listing Extension — 6-K · Jun 25, 2024
- NLS Pharmaceutics files patent for novel sleep disorder treatment — 6-K · Jun 11, 2024
- NLS Pharmaceutics Sets Shareholder Meeting for June 27 — 6-K · Jun 6, 2024
- NLS Pharmaceutics CMO Resigns; Interim CMO Appointed — 6-K · May 31, 2024
- NLS Pharmaceutics Reports Positive Mazindol Study Results — 6-K · May 28, 2024
- NLS Pharmaceutics Receives Nasdaq Delisting Determination — 6-K · May 24, 2024
- NLS Pharmaceutics Adds to Shareholder Bridge Loans — 6-K · May 22, 2024
- NLS Pharmaceutics Ltd. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · May 15, 2024
- NLS Pharmaceutics Adds to Short-Term Loan Agreements — 6-K · May 14, 2024
- NLS Pharmaceutics Faces Nasdaq Delisting, Seeks Hearing — 6-K · Apr 19, 2024
- NLS Pharmaceutics Increases Share Capital by CHF 76,439.38 — 6-K · Apr 15, 2024
- NLS Pharmaceutics Director Resigns, Board Seat Not Replaced — 6-K · Apr 8, 2024
- Nls Pharmaceutics LTD. SC 13G Filing — SC 13G · Mar 27, 2024
- NLS Pharmaceutics Prices $1.75M Direct Offering — 6-K · Mar 21, 2024